SG11201707166TA - Anti-inflammatory polypeptides - Google Patents
Anti-inflammatory polypeptidesInfo
- Publication number
- SG11201707166TA SG11201707166TA SG11201707166TA SG11201707166TA SG11201707166TA SG 11201707166T A SG11201707166T A SG 11201707166TA SG 11201707166T A SG11201707166T A SG 11201707166TA SG 11201707166T A SG11201707166T A SG 11201707166TA SG 11201707166T A SG11201707166T A SG 11201707166TA
- Authority
- SG
- Singapore
- Prior art keywords
- inflammatory polypeptides
- polypeptides
- inflammatory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/638,905 US9845358B2 (en) | 2011-12-19 | 2015-03-04 | Anti-inflammatory polypeptides |
| PCT/US2016/020813 WO2016141262A1 (en) | 2015-03-04 | 2016-03-04 | Anti-inflammatory polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201707166TA true SG11201707166TA (en) | 2017-09-28 |
Family
ID=56848864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201707166TA SG11201707166TA (en) | 2015-03-04 | 2016-03-04 | Anti-inflammatory polypeptides |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10844125B2 (en) |
| EP (1) | EP3265124A4 (en) |
| JP (1) | JP2018508522A (en) |
| KR (1) | KR20230028600A (en) |
| CN (1) | CN107847586A (en) |
| AU (1) | AU2016226115B2 (en) |
| CA (1) | CA2978580A1 (en) |
| EA (2) | EA202191471A1 (en) |
| IL (1) | IL254284B2 (en) |
| SG (1) | SG11201707166TA (en) |
| WO (1) | WO2016141262A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8470318B2 (en) * | 2005-11-07 | 2013-06-25 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| JP7122002B2 (en) * | 2017-03-01 | 2022-08-19 | 国立大学法人北海道大学 | Method for producing a disease model non-human animal, disease model non-human animal, drug screening method using the animal, and disease risk determination method |
| CN112924671A (en) * | 2021-01-28 | 2021-06-08 | 中国医学科学院北京协和医院 | Biomarker for diagnosing rheumatoid arthritis combined with pulmonary interstitial fibrosis and application thereof |
| WO2023104128A1 (en) | 2021-12-09 | 2023-06-15 | 上海宝济药业有限公司 | Fc polypeptide having altered glycosylation modification |
| WO2024071010A1 (en) * | 2022-09-26 | 2024-04-04 | 国立大学法人京都大学 | T cell production method |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| CA2595169A1 (en) | 2005-01-12 | 2006-07-20 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
| BRPI0611445A2 (en) | 2005-05-09 | 2010-09-08 | Glycart Biotechnology Ag | glycomanipulated antigen binding molecule, polynucleotide, polypeptide, vector, host cell, method for production, use and pharmaceutical composition |
| DK1896071T3 (en) | 2005-06-30 | 2015-05-26 | Janssen Biotech Inc | Methods and compositions with increased therapeutic activity |
| WO2007055916A2 (en) | 2005-11-07 | 2007-05-18 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
| US8470318B2 (en) * | 2005-11-07 | 2013-06-25 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| EP3456351A1 (en) | 2006-04-05 | 2019-03-20 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| NZ597651A (en) | 2006-10-26 | 2012-07-27 | Univ Rockefeller | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| MX2009006659A (en) | 2006-12-20 | 2009-10-12 | Mmr Information Systems Inc | Antibodies and methods for making and using them. |
| US8540992B2 (en) | 2006-12-28 | 2013-09-24 | Michael Naso | Methods and vectors for generating asialylated immunoglobulins |
| US20110020269A1 (en) * | 2007-05-08 | 2011-01-27 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for modifying t cell immune responses and inflammation |
| CN101687933B (en) | 2007-05-30 | 2015-11-25 | 浦项工科大学校产学协力团 | Domain-immunoglobulin fusion proteins |
| JP5647899B2 (en) | 2008-01-08 | 2015-01-07 | ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ | Glycoconjugation of polypeptides using oligosaccharyltransferase |
| EP2279410B1 (en) | 2008-04-22 | 2015-11-11 | The Rockefeller University | Methods of identifying anti-inflammatory compounds |
| WO2011059684A1 (en) | 2009-10-29 | 2011-05-19 | Centocor Ortho Biotech Inc. | Antibody glycosylation variants |
| TW202323302A (en) | 2010-11-30 | 2023-06-16 | 日商中外製藥股份有限公司 | Cytotoxicity-inducing therapeutic agent |
| US20120258041A1 (en) | 2011-04-07 | 2012-10-11 | Basi Guriqbal S | Compositions and methods for treating diseases of protein aggregation involving ic3b deposition |
| BR112014014549A2 (en) * | 2011-12-19 | 2020-09-24 | The Rockefeller University | non-sialylated popipeptide anti-inflammatory |
-
2016
- 2016-03-04 AU AU2016226115A patent/AU2016226115B2/en active Active
- 2016-03-04 SG SG11201707166TA patent/SG11201707166TA/en unknown
- 2016-03-04 KR KR1020177028445A patent/KR20230028600A/en unknown
- 2016-03-04 EA EA202191471A patent/EA202191471A1/en unknown
- 2016-03-04 WO PCT/US2016/020813 patent/WO2016141262A1/en active Application Filing
- 2016-03-04 US US15/555,194 patent/US10844125B2/en active Active
- 2016-03-04 EP EP16759551.1A patent/EP3265124A4/en not_active Withdrawn
- 2016-03-04 JP JP2017546144A patent/JP2018508522A/en active Pending
- 2016-03-04 CA CA2978580A patent/CA2978580A1/en active Pending
- 2016-03-04 CN CN201680025702.2A patent/CN107847586A/en active Pending
- 2016-03-04 EA EA201791937A patent/EA038554B1/en unknown
-
2017
- 2017-09-03 IL IL254284A patent/IL254284B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10844125B2 (en) | 2020-11-24 |
| JP2018508522A (en) | 2018-03-29 |
| IL254284B1 (en) | 2023-03-01 |
| US20180051087A1 (en) | 2018-02-22 |
| EA038554B1 (en) | 2021-09-14 |
| EP3265124A4 (en) | 2018-09-12 |
| EP3265124A1 (en) | 2018-01-10 |
| CA2978580A1 (en) | 2016-09-09 |
| AU2016226115A1 (en) | 2017-10-19 |
| AU2016226115B2 (en) | 2021-03-25 |
| IL254284B2 (en) | 2023-07-01 |
| EA201791937A1 (en) | 2018-07-31 |
| CN107847586A (en) | 2018-03-27 |
| KR20230028600A (en) | 2023-02-28 |
| WO2016141262A1 (en) | 2016-09-09 |
| IL254284A0 (en) | 2017-10-31 |
| EA202191471A1 (en) | 2022-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201802261B (en) | Polypeptides | |
| IL262482A (en) | Novel polypeptides | |
| IL255767A (en) | Novel polypeptides | |
| HK1250041A1 (en) | Polypeptides | |
| ZA201702537B (en) | Peptides having anti-inflammatory properties | |
| GB201611530D0 (en) | Novel polypeptides | |
| ZA201704366B (en) | Il-17a-binding polypeptides | |
| HK1250040A1 (en) | Polypeptides | |
| IL254284B1 (en) | Anti-inflammatory polypeptides | |
| ZA201701348B (en) | New polypeptides | |
| GB201520536D0 (en) | Peptides | |
| GB201520546D0 (en) | Peptides | |
| GB201619652D0 (en) | Novel polypeptides | |
| GB201520545D0 (en) | Peptides | |
| GB201520541D0 (en) | Peptides | |
| GB201520550D0 (en) | Peptides | |
| GB201520543D0 (en) | Peptides | |
| GB201520539D0 (en) | Peptides | |
| GB201520544D0 (en) | Peptides | |
| GB201520542D0 (en) | Peptides | |
| GB201520548D0 (en) | Peptides | |
| GB201515245D0 (en) | Novel polypeptides | |
| GB201520535D0 (en) | Peptides | |
| GB201520538D0 (en) | Peptides | |
| GB201520534D0 (en) | Peptides |